MARKET

VIR

VIR

VIR BIOTECHNOLOG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

63.89
+0.04
+0.06%
Opening 13:06 02/24 EST
OPEN
64.01
PREV CLOSE
63.85
HIGH
65.79
LOW
62.19
VOLUME
262.27K
TURNOVER
--
52 WEEK HIGH
141.01
52 WEEK LOW
17.03
MARKET CAP
8.14B
P/E (TTM)
-9.9791
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings
Biotech stocks pulled back along with the broader market in the holiday-shortened week ended Feb 19. Earnings news flow was light before picking up pace in the unfolding week.
Benzinga · 4d ago
Glaxo (GSK)/Vir Biotech to Develop Antibodies for Influenza
Zacks.com · 6d ago
Company News for Feb 18, 2021
Zacks.com · 6d ago
Analysts Estimate Vir Biotechnology, Inc. (VIR) to Report a Decline in Earnings: What to Look Out for
Zacks.com · 6d ago
GSK, Vir Biotech to expand COVID-19 research partnership for other diseases
GlaxoSmithKline and Vir Biotechnology Inc will expand an existing partnership developing antibody therapies for COVID-19 to other diseases, the companies said on Wednesday.
Reuters · 6d ago
Vir Biotech CEO on the expanded GSK partnership
George Scangos, CEO of VIR Biotechnology, joins "Squawk Alley" to discuss the company's expanded partnership with GlaxoSmithKline as well as Covid antibody treatments.
CNBC.com · 02/17 17:18
Stocks making the biggest moves midday: Wells Fargo, Palantir, Shopify and more
These are the stocks posting the largest moves in midday trading.
CNBC.com · 02/17 17:05
Wednesday's ETF with Unusual Volume: MOON
Feb 17, 2021 (MarketNewsVideo.com via COMTEX) -- The Direxion Moonshot Innovators ETF is seeing unusually high volume in afternoon trading Wednesday, with...
MarketNewsVideo.com · 02/17 17:04
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIR. Analyze the recent business situations of VIR BIOTECHNOLOG through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VIR stock price target is 74.40 with a high estimate of 125.00 and a low estimate of 54.00.
EPS
Institutional Holdings
Institutions: 194
Institutional Holdings: 78.36M
% Owned: 61.51%
Shares Outstanding: 127.39M
TypeInstitutionsShares
Increased
53
5.40M
New
61
3.82M
Decreased
24
335.13K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.96%
Pharmaceuticals & Medical Research
+1.20%
Key Executives
Chairman/Independent Director
Vicki Sato
Chairman/Independent Director
vicki Sato
President/Chief Executive Officer/Director
George Scangos
Co-Founder
Jay Parrish
Chief Financial Officer/Secretary
Howard Horn
Executive Vice President/Chief Scientific Officer
Virgin Virgin
Executive Vice President/Chief Scientific Officer
Herbert Virgin
Chief Technology Officer
Michael Kamarck
Other
Phil Pang
Director
Jeffrey Hatfield
Director
Janet Napolitano
Independent Director
Robert More
Independent Director
Robert Nelsen
Independent Director
Dipchand Nishar
Independent Director
Robert Perez
Independent Director
Saira Ramasastry
Independent Director
Phillip Sharp
Independent Director
Elliott Sigal
  • Dividends
  • Splits
  • Insider Activity
No Data
About VIR
Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.

Webull offers kinds of Vir Biotechnology Inc stock information, including NASDAQ:VIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIR stock methods without spending real money on the virtual paper trading platform.